Insulin receptor isoform a and insulin-Like growth factor II as additional treatment targets in human osteosarcoma

Sofia Avnet, Laura Sciacca, Manuela Salerno, Giovanni Gancitano, Maria Francesca Cassarino, Alessandra Longhi, Mahvash Zakikhani, Joan M. Carboni, Marco Gottardis, Armando Giunti, Michael Pollak, Riccardo Vigneri, Nicola Baldini

Research output: Contribution to journalArticle

Abstract

Despite the frequent presence of an insulin-like growth factor I receptor (IGFIR)-mediated autocrine loop in osteosarcoma (OS), interfering with this target was only moderately effective in preclinical studies. Here, we considered other members of the IGF system that might be involved in the molecular pathology of OS. We found that, among 45 patients with OS, IGF-I and IGFBP-3 serum levels were significantly lower, and IGF-H serum levels significantly higher, than healthy controls. Increased IGF-II values were associated with a decreased disease-free survival. After tumor removal, both 1GF-1 and IGF-II levels returned to normal values. In 23 of 45 patients, we obtained tissue specimens and found that all expressed high mRNA level of IGF-II and >IGF-I. Also, isoform A of the insulin receptor (IR-A) was expressed at high level in addition to IGFIR and IR-A/IGFIR hybrids receptors (HR A). These receptors were also expressed in OS cell lines, and simultaneous impairment of IGFIR, IR, and Hybrid-Rs by monoclonal antibodies, siRNA, or the tyrosine kinase inhibitor BMS-536924, which blocks both IGFIR and IR, was more effective than selective anti-IGFIR strategies. Also, anti-IGF-II-siRNA treatment in low-serum conditions significantly inhibited MG-63 OS cells that have an autocrine circuit for IGF-II. In summary, IGF-II rather than IGF-I is the predominant growth factor produced by OS cells, and three different receptors (IR-A, HR A, and IGFIR) act complementarily for an IGF II- mediated constitutive autocrine loop, in addition to the previously shown IGFIR/IGF-I circuit. Cotargeting IGFIR and IR-A is more effective than targeting IGF-IR alone in inhibiting OS growth.

Original languageEnglish
Pages (from-to)2443-2452
Number of pages10
JournalCancer Research
Volume69
Issue number6
DOIs
Publication statusPublished - Mar 15 2009

Fingerprint

IGF Type 1 Receptor
Insulin-Like Growth Factor II
Insulin Receptor
Osteosarcoma
Protein Isoforms
Insulin-Like Growth Factor I
Therapeutics
Small Interfering RNA
Serum
Insulin-Like Growth Factor Binding Protein 3
Molecular Pathology
Protein-Tyrosine Kinases
Disease-Free Survival
Intercellular Signaling Peptides and Proteins
Reference Values
Monoclonal Antibodies
Cell Line
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Insulin receptor isoform a and insulin-Like growth factor II as additional treatment targets in human osteosarcoma. / Avnet, Sofia; Sciacca, Laura; Salerno, Manuela; Gancitano, Giovanni; Cassarino, Maria Francesca; Longhi, Alessandra; Zakikhani, Mahvash; Carboni, Joan M.; Gottardis, Marco; Giunti, Armando; Pollak, Michael; Vigneri, Riccardo; Baldini, Nicola.

In: Cancer Research, Vol. 69, No. 6, 15.03.2009, p. 2443-2452.

Research output: Contribution to journalArticle

Avnet, S, Sciacca, L, Salerno, M, Gancitano, G, Cassarino, MF, Longhi, A, Zakikhani, M, Carboni, JM, Gottardis, M, Giunti, A, Pollak, M, Vigneri, R & Baldini, N 2009, 'Insulin receptor isoform a and insulin-Like growth factor II as additional treatment targets in human osteosarcoma', Cancer Research, vol. 69, no. 6, pp. 2443-2452. https://doi.org/10.1158/0008-5472.CAN-08-2645
Avnet, Sofia ; Sciacca, Laura ; Salerno, Manuela ; Gancitano, Giovanni ; Cassarino, Maria Francesca ; Longhi, Alessandra ; Zakikhani, Mahvash ; Carboni, Joan M. ; Gottardis, Marco ; Giunti, Armando ; Pollak, Michael ; Vigneri, Riccardo ; Baldini, Nicola. / Insulin receptor isoform a and insulin-Like growth factor II as additional treatment targets in human osteosarcoma. In: Cancer Research. 2009 ; Vol. 69, No. 6. pp. 2443-2452.
@article{e86363d00f2947e5aa52197f0b6fcda5,
title = "Insulin receptor isoform a and insulin-Like growth factor II as additional treatment targets in human osteosarcoma",
abstract = "Despite the frequent presence of an insulin-like growth factor I receptor (IGFIR)-mediated autocrine loop in osteosarcoma (OS), interfering with this target was only moderately effective in preclinical studies. Here, we considered other members of the IGF system that might be involved in the molecular pathology of OS. We found that, among 45 patients with OS, IGF-I and IGFBP-3 serum levels were significantly lower, and IGF-H serum levels significantly higher, than healthy controls. Increased IGF-II values were associated with a decreased disease-free survival. After tumor removal, both 1GF-1 and IGF-II levels returned to normal values. In 23 of 45 patients, we obtained tissue specimens and found that all expressed high mRNA level of IGF-II and >IGF-I. Also, isoform A of the insulin receptor (IR-A) was expressed at high level in addition to IGFIR and IR-A/IGFIR hybrids receptors (HR A). These receptors were also expressed in OS cell lines, and simultaneous impairment of IGFIR, IR, and Hybrid-Rs by monoclonal antibodies, siRNA, or the tyrosine kinase inhibitor BMS-536924, which blocks both IGFIR and IR, was more effective than selective anti-IGFIR strategies. Also, anti-IGF-II-siRNA treatment in low-serum conditions significantly inhibited MG-63 OS cells that have an autocrine circuit for IGF-II. In summary, IGF-II rather than IGF-I is the predominant growth factor produced by OS cells, and three different receptors (IR-A, HR A, and IGFIR) act complementarily for an IGF II- mediated constitutive autocrine loop, in addition to the previously shown IGFIR/IGF-I circuit. Cotargeting IGFIR and IR-A is more effective than targeting IGF-IR alone in inhibiting OS growth.",
author = "Sofia Avnet and Laura Sciacca and Manuela Salerno and Giovanni Gancitano and Cassarino, {Maria Francesca} and Alessandra Longhi and Mahvash Zakikhani and Carboni, {Joan M.} and Marco Gottardis and Armando Giunti and Michael Pollak and Riccardo Vigneri and Nicola Baldini",
year = "2009",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-08-2645",
language = "English",
volume = "69",
pages = "2443--2452",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Insulin receptor isoform a and insulin-Like growth factor II as additional treatment targets in human osteosarcoma

AU - Avnet, Sofia

AU - Sciacca, Laura

AU - Salerno, Manuela

AU - Gancitano, Giovanni

AU - Cassarino, Maria Francesca

AU - Longhi, Alessandra

AU - Zakikhani, Mahvash

AU - Carboni, Joan M.

AU - Gottardis, Marco

AU - Giunti, Armando

AU - Pollak, Michael

AU - Vigneri, Riccardo

AU - Baldini, Nicola

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Despite the frequent presence of an insulin-like growth factor I receptor (IGFIR)-mediated autocrine loop in osteosarcoma (OS), interfering with this target was only moderately effective in preclinical studies. Here, we considered other members of the IGF system that might be involved in the molecular pathology of OS. We found that, among 45 patients with OS, IGF-I and IGFBP-3 serum levels were significantly lower, and IGF-H serum levels significantly higher, than healthy controls. Increased IGF-II values were associated with a decreased disease-free survival. After tumor removal, both 1GF-1 and IGF-II levels returned to normal values. In 23 of 45 patients, we obtained tissue specimens and found that all expressed high mRNA level of IGF-II and >IGF-I. Also, isoform A of the insulin receptor (IR-A) was expressed at high level in addition to IGFIR and IR-A/IGFIR hybrids receptors (HR A). These receptors were also expressed in OS cell lines, and simultaneous impairment of IGFIR, IR, and Hybrid-Rs by monoclonal antibodies, siRNA, or the tyrosine kinase inhibitor BMS-536924, which blocks both IGFIR and IR, was more effective than selective anti-IGFIR strategies. Also, anti-IGF-II-siRNA treatment in low-serum conditions significantly inhibited MG-63 OS cells that have an autocrine circuit for IGF-II. In summary, IGF-II rather than IGF-I is the predominant growth factor produced by OS cells, and three different receptors (IR-A, HR A, and IGFIR) act complementarily for an IGF II- mediated constitutive autocrine loop, in addition to the previously shown IGFIR/IGF-I circuit. Cotargeting IGFIR and IR-A is more effective than targeting IGF-IR alone in inhibiting OS growth.

AB - Despite the frequent presence of an insulin-like growth factor I receptor (IGFIR)-mediated autocrine loop in osteosarcoma (OS), interfering with this target was only moderately effective in preclinical studies. Here, we considered other members of the IGF system that might be involved in the molecular pathology of OS. We found that, among 45 patients with OS, IGF-I and IGFBP-3 serum levels were significantly lower, and IGF-H serum levels significantly higher, than healthy controls. Increased IGF-II values were associated with a decreased disease-free survival. After tumor removal, both 1GF-1 and IGF-II levels returned to normal values. In 23 of 45 patients, we obtained tissue specimens and found that all expressed high mRNA level of IGF-II and >IGF-I. Also, isoform A of the insulin receptor (IR-A) was expressed at high level in addition to IGFIR and IR-A/IGFIR hybrids receptors (HR A). These receptors were also expressed in OS cell lines, and simultaneous impairment of IGFIR, IR, and Hybrid-Rs by monoclonal antibodies, siRNA, or the tyrosine kinase inhibitor BMS-536924, which blocks both IGFIR and IR, was more effective than selective anti-IGFIR strategies. Also, anti-IGF-II-siRNA treatment in low-serum conditions significantly inhibited MG-63 OS cells that have an autocrine circuit for IGF-II. In summary, IGF-II rather than IGF-I is the predominant growth factor produced by OS cells, and three different receptors (IR-A, HR A, and IGFIR) act complementarily for an IGF II- mediated constitutive autocrine loop, in addition to the previously shown IGFIR/IGF-I circuit. Cotargeting IGFIR and IR-A is more effective than targeting IGF-IR alone in inhibiting OS growth.

UR - http://www.scopus.com/inward/record.url?scp=65549161522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549161522&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-2645

DO - 10.1158/0008-5472.CAN-08-2645

M3 - Article

C2 - 19258511

AN - SCOPUS:65549161522

VL - 69

SP - 2443

EP - 2452

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 6

ER -